PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'MAMC Medical College and Lok Nayak Jai Prakash Narayan Hospital, New Delhi, India.\', \'Topiwala National Medical College & B. Y. L. Nair Charitable Hospital, Mumbai, Maharashtra, India.\', \'Seth GS Medical College and KEM Hospital, Mumbai, Maharashtra, India.\', \'All India Institute of Medical Sciences, New Delhi, India.\', \'Indian College of Physicians and Lilavati Hospital, Mumbai, Maharashtra, India.\', \'Biocon Biologics India Ltd, Bengaluru, Karnataka, India.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1080/14712598.2021.1905794
?:doi
?:hasPublicationType
?:journal
  • Expert opinion on biological therapy
is ?:pmid of
?:pmid
?:pmid
  • 33835886
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.117
?:rankingScore_hIndex
  • 73
is ?:relation_isRelatedTo_publication of
?:title
  • A two-arm, randomized, controlled, multi-centric, open-label phase-2 study to evaluate the efficacy and safety of Itolizumab in moderate to severe ARDS patients due to COVID-19.
?:type
?:year
  • 2021

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/33835886>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/33835886>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all